Loading clinical trials...
Loading clinical trials...
Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study]
Conditions
Interventions
rituximab
cyclophosphamide
+3 more
Locations
78
Germany
Haematologisch Onkologische Praxis
Aachen, Germany
Klinikum Augsburg
Augsburg, Germany
Klinikum Bayreuth
Bayreuth, Germany
Haematologisch-Onkologische Schwerpunktpraxis - Weilheim
Berlin, Germany
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, Germany
Franziskus Hospital
Bielefeld, Germany
Start Date
November 1, 2005
Primary Completion Date
August 1, 2018
Completion Date
August 1, 2018
Last Updated
March 11, 2021
NCT06263491
NCT06337318
NCT05139017
NCT05529069
NCT07388563
NCT07350863
Lead Sponsor
German High-Grade Non-Hodgkin's Lymphoma Study Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions